Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor
Status:
Completed
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
Study 110 is a Phase 3, multicenter study in subjects aged 6 years and older with cystic
fibrosis (CF) who are homozygous for the F508del-CF transmembrane conductance regulator
(CFTR) mutation and who participated in Study 109 (NCT02514473) or Study 011B (NCT01897233).
Study 110 is designed to evaluate the safety and efficacy of long term treatment of
lumacaftor in combination with ivacaftor.